DexCom Inc (DXCM)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $31.08B
Last updated: Nov 17, 2026 at 11:05 AM ET
DexCom Inc (DXCM) Earnings: Report Dates and Results
DexCom (DXCM) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, DexCom reported EPS of $0.73, above the $0.66 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
DXCM has an expected report date of Feb 10, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 7.4% above the $0.68 reported for the quarter ended Dec 31, 2025.
DXCM Earnings Call
The latest DXCM earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, DXCM beat 28, missed 7 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $1.34B, up 10.7% from $1.21B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.73 | $0.66 | $0.63 - $0.72 | +10.61% | Beat | +19.7% | 22 | 1 up, 1 down | Oct 29, 2026 | $1.34B |
| Jun 30, 2026 | $0.70 | $0.61 | $0.57 - $0.66 | +14.75% | Beat | +45.8% | 21 | 10 up, 4 down | Jul 30, 2026 | $1.31B |
| Mar 31, 2026 | $0.56 | $0.47 | $0.42 - $0.53 | +19.15% | Beat | +75.0% | 21 | 1 up, 0 down | Apr 30, 2026 | $1.19B |
| Dec 31, 2025 | $0.68 | $0.65 | $0.59 - $0.73 | +4.62% | Beat | +51.1% | 23 | 6 up, 1 down | Feb 12, 2026 | $1.26B |
| Sep 30, 2025 | $0.61 | $0.57 | $0.52 - $0.61 | +7.02% | Beat | +35.6% | 23 | 3 up, 0 down | Oct 30, 2025 | $1.21B |
| Jun 30, 2025 | $0.48 | $0.44 | $0.42 - $0.49 | +9.09% | Beat | +11.6% | 23 | 1 up, 3 down | Jul 30, 2025 | $1.16B |
| Mar 31, 2025 | $0.32 | $0.33 | $0.28 - $0.43 | -3.03% | Miss | 0.0% | 22 | 1 up, 2 down | May 1, 2025 | $1.04B |
| Dec 31, 2024 | $0.45 | $0.50 | $0.41 - $0.59 | -10.00% | Miss | -10.0% | 20 | 0 up, 8 down | Feb 13, 2025 | $1.11B |
| Sep 30, 2024 | $0.45 | $0.43 | $0.40 - $0.48 | +4.65% | Beat | -10.0% | 20 | 1 up, 0 down | Oct 24, 2024 | $994.20M |
| Jun 30, 2024 | $0.43 | $0.39 | $0.34 - $0.42 | +10.26% | Beat | +26.5% | 20 | 0 up, 1 down | Jul 25, 2024 | $1.00B |
| Mar 31, 2024 | $0.32 | $0.27 | $0.21 - $0.34 | +18.52% | Beat | +88.2% | 20 | 1 up, 0 down | Apr 25, 2024 | $921.00M |
| Dec 31, 2023 | $0.50 | $0.43 | $0.37 - $0.48 | +16.28% | Beat | +47.1% | 18 | 5 up, 0 down | Feb 8, 2024 | $1.03B |
| Sep 30, 2023 | $0.50 | $0.33 | $0.26 - $0.46 | +51.52% | Beat | +78.6% | 19 | 0 up, 0 down | Oct 26, 2023 | $975.00M |
| Jun 30, 2023 | $0.34 | $0.23 | $0.16 - $0.30 | +47.83% | Beat | +100.0% | 19 | 0 up, 0 down | Jul 27, 2023 | $871.30M |
| Mar 31, 2023 | $0.17 | $0.15 | $0.08 - $0.20 | +13.33% | Beat | +112.5% | 18 | 0 up, 0 down | Apr 27, 2023 | $741.50M |
| Dec 31, 2022 | $0.34 | $0.28 | $0.23 - $0.30 | +21.43% | Beat | +100.0% | 18 | 2 up, 0 down | Feb 9, 2023 | $815.20M |
| Sep 30, 2022 | $0.28 | $0.24 | $0.21 - $0.27 | +16.67% | Beat | +27.3% | 17 | 0 up, 1 down | Oct 27, 2022 | $769.60M |
| Jun 30, 2022 | $0.17 | $0.19 | $0.13 - $0.25 | -10.53% | Miss | -10.5% | 17 | 0 up, 0 down | Jul 28, 2022 | $696.20M |
| Mar 31, 2022 | $0.08 | $0.13 | $0.06 - $0.18 | -38.46% | Miss | 0.0% | 17 | 0 up, 0 down | Apr 28, 2022 | $628.80M |
| Dec 31, 2021 | $0.17 | $0.21 | $0.13 - $0.24 | -19.05% | Miss | -26.1% | 18 | 1 up, 0 down | Feb 10, 2022 | $698.20M |
| Sep 30, 2021 | $0.22 | $0.16 | $0.12 - $0.19 | +37.50% | Beat | -8.3% | 21 | 1 up, 0 down | Oct 28, 2021 | $650.20M |
| Jun 30, 2021 | $0.19 | $0.11 | $0.06 - $0.16 | +72.73% | Beat | -5.0% | 21 | N/A | Jul 29, 2021 | $595.10M |
| Mar 31, 2021 | $0.08 | $0.07 | $0.06 - $0.50 | +14.29% | Beat | -27.3% | 19 | N/A | Apr 29, 2021 | $505.00M |
| Dec 31, 2020 | $0.23 | $0.23 | $0.18 - $0.28 | 0.00% | In line | -20.7% | 18 | N/A | Feb 11, 2021 | $568.90M |
| Sep 30, 2020 | $0.24 | $0.16 | $0.12 - $0.21 | +50.00% | Beat | +50.0% | 19 | N/A | Oct 27, 2020 | $500.90M |
| Jun 30, 2020 | $0.20 | $0.09 | -$0.10 - $0.59 | +122.22% | Beat | +900.0% | 18 | N/A | Jul 28, 2020 | $451.80M |
| Mar 31, 2020 | $0.11 | $0.04 | -$0.07 - $0.45 | +175.00% | Beat | N/A | 17 | N/A | Apr 28, 2020 | $405.10M |
| Dec 31, 2019 | $0.29 | $0.18 | $0.14 - $0.25 | +61.11% | Beat | +107.1% | 17 | N/A | Feb 13, 2020 | $462.80M |
| Sep 30, 2019 | $0.16 | $0.20 | $0.08 - $0.34 | -20.00% | Miss | +300.0% | 17 | N/A | Nov 6, 2019 | $396.30M |
| Jun 30, 2019 | $0.02 | $0.01 | -$0.12 - $0.17 | +100.00% | Beat | N/A | 16 | N/A | Jul 31, 2019 | $336.40M |
| Mar 31, 2019 | -$0.01 | -$0.01 | -$0.44 - $0.18 | 0.00% | In line | N/A | 16 | N/A | May 1, 2019 | $280.50M |
| Dec 31, 2018 | $0.14 | $0.16 | $0.10 - $0.32 | -12.50% | Miss | +366.7% | 18 | N/A | Feb 21, 2019 | $338.00M |
| Sep 30, 2018 | $0.04 | -$0.02 | -$0.29 - $0.03 | +300.00% | Beat | N/A | 16 | N/A | Nov 6, 2018 | $266.70M |
| Jun 30, 2018 | -$0.02 | -$0.04 | -$0.07 - -$0.02 | +50.00% | Beat | N/A | 19 | N/A | Aug 1, 2018 | $242.50M |
| Mar 31, 2018 | -$0.08 | -$0.09 | -$0.51 - -$0.01 | +11.11% | Beat | N/A | 18 | N/A | May 2, 2018 | $184.40M |
| Dec 31, 2017 | $0.03 | $0.01 | -$0.10 - $0.13 | +200.00% | Beat | N/A | 17 | N/A | Feb 27, 2018 | $221.00M |
| Sep 30, 2017 | -$0.01 | -$0.01 | N/A | 0.00% | In line | N/A | 18 | N/A | Nov 1, 2017 | $184.60M |
| Jun 30, 2017 | -$0.04 | -$0.06 | -$0.09 - -$0.03 | +33.33% | Beat | N/A | 16 | N/A | Aug 1, 2017 | $170.60M |
| Mar 31, 2017 | -$0.12 | -$0.12 | N/A | 0.00% | In line | N/A | N/A | N/A | May 2, 2017 | $142.30M |
| Dec 31, 2016 | -$0.02 | -$0.02 | N/A | 0.00% | In line | -300.0% | N/A | N/A | Feb 28, 2017 | $171.20M |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $2.09, up 26.7% from the year before. It was -$0.19 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $2.09 | +26.7% |
| Dec 31, 2024 | $1.65 | +9.3% |
| Dec 31, 2023 | $1.51 | +73.6% |
| Dec 31, 2022 | $0.87 | +31.8% |
| Dec 31, 2021 | $0.66 | -15.4% |
| Dec 31, 2020 | $0.78 | +69.6% |
| Dec 31, 2019 | $0.46 | +475.0% |
| Dec 31, 2018 | $0.08 | N/A |
| Dec 31, 2017 | -$0.14 | N/A |
| Dec 31, 2016 | -$0.19 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,700 words across 19 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,680 | 19 | |
| 2026Q2 | Jun 30, 2026 | 7,445 | 19 | |
| 2026Q1 | Mar 31, 2026 | 8,713 | 24 | |
| 2025Q4 | Dec 31, 2025 | 6,988 | 20 | |
| 2025Q3 | Sep 30, 2025 | 9,293 | 24 | |
| 2025Q2 | Jun 30, 2025 | 8,895 | 23 | |
| 2025Q1 | Mar 31, 2025 | 9,135 | 25 | |
| 2024Q4 | Dec 31, 2024 | 11,454 | 24 |
2026Q3 Earnings Call
Opening remarks
Sean Christensen Senior Vice President of Finance and Investor Relations Thank you, operator, and welcome to Dexcom's Third Quarter 2026 Earnings Call. Our agenda begins with Jake Leach, Dexcom's President and CEO, who will summarize our recent highlights and ongoing strategic initiatives, followed by a financial review and outlook from Jereme Sylvain, our Chief Operating Officer and Chief Financial Officer. Following our prepared remarks, we will open the call up for your questions. At that time, we ask analysts to limit themselves to one question each so we can provide an opportunity for everyone participating today. Please note that there are also slides available related to our third quarter 2026 performance on the Dexcom Investor Relations website on the Events and Presentations page. With that, let's review our safe harbor statement. Some statements on today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs, and expectations about future events, strategies, competition, products, operating plans, and performance. These statements are made as of the date hereof based on information currently available to Dexcom and are subject to various risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please see Dexcom's annual report on Form 10-K, most recent quarterly report on Form 10-Q, and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any forward-looking statement or to conform any forward-looking statements to actual results. Additionally, during the call, we will discuss certain non-GAAP financial measures. Unless otherwise noted, all financial measures discussed on this call are presented on a non-GAAP basis. Non-GAAP measures should not be considered in isolation or as a substitute for or superior to GAAP results. Please refer to the tables in our earnings release and the slides accompanying our third quarter 2026 earnings call for reconciliations to the most directly comparable GAAP measure. Now I will turn it over to Jake.
Jacob Leach President and CEO Thank you, Sean, and thank you, everyone, for joining us. Today, we reported third quarter revenue growth of 11% compared to the third quarter of 2025 on both a reported and organic basis. Underlying our third quarter results are four key areas that advance our long-term vision we provided earlier this year. First, we continue to see strong momentum across the CGM category, driving our stable low double-digit revenue growth with active base growth above those levels. We once again gained share in the quarter, supported by prescriber and customer preference for Dexcom CGM, positioning us well as we prepare for significant access expansion. Second, our clinical evidence continues to strengthen the case for broader access to CGM.
Frequently Asked Questions About DXCM
When is DexCom's next earnings date?
DexCom's next earnings report is expected for Feb 10, 2027.
Did DXCM beat earnings estimates last quarter?
Yes. DexCom reported EPS of $0.73 for the quarter ended Sep 30, 2026, above the $0.66 estimate, a 10.61% surprise.
What EPS do analysts expect from DXCM next quarter?
The consensus EPS estimate for DexCom for the quarter ending Dec 31, 2026 is $0.73 from 28 analysts, with estimates from $0.66 to $0.84.
How often does DXCM beat earnings estimates?
DexCom beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +6.53%.
DXCM pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors